28 completed, 10 unknown, 4 not yet recruiting, 3 recruiting. 14 Phase 2, 12 Phase 1, 11 Phase 3, 7 Not applicable, 2 Phase 4.
Follow Terbinafine: new trials by email Literature Review of Terbinafine trials Research Report on Terbinafine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Systemic Antifungal Plus Q-Switched Nd:YAG Laser for Onychomycosis Terbinafine, Q-switched Nd:YAG laser - Onychomycosis | Not applicable | Not yet recruiting | Assiut University | 97 | 2026-10-10 | 2026-10-09 |
| Terbinafine for CSA-AKI Prevention Terbinafine - Acute Kidney Injury, Cardiac Surgical Procedures | Phase 2 | Not yet recruiting | Guangdong Provincial People's Hospital | 208 | 2026-09-01 | 2026-07-31 |
| Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro) Terbinafine - Recurrent Prostate Cancer | Phase 2 | Recruiting | Swiss Cancer Institute | 42 | 2026-04-24 | 2026-10-28 |
| A Phase 2 Study to Assess the Effectiveness of Topical Terbinafine in Participants With Mild to Moderate Onychomycosis of the Toenails 2.4% Topical Terbinafine, 10% Topical Efinaconazole, Vehicle Control - Onychomycosis of Toenail | Phase 2 | Not yet recruiting | Onyx Axiom | 200 | 2026-03-01 | 2026-02-04 |
| Efficacy of Ultraviolet B Phototherapy in the Management of Resistant and Relapsing Tinea Corporis and Tinea Cruris NBUVB, Itraconazole + terbinafine - Fungal Resistance | Not applicable | Not yet recruiting | Cairo University | 36 | 2025-12-01 | 2025-11-21 |
| Topical Terbinafine Versus Hydrocortisone Combined With Oral Itraconazole for Seborrheic Dermatitis Itraconazole, Terbinafine 1% cream, Hydrocortisone 1% cream - Seborrheic Dermatitis | Phase 4 | Completed | Can Tho University of Medicine and Pharmacy | 76 | 2025-07-07 | 2026-10-30 |
| Efficacy Comparison of Itraconazole Pulse Therapy and Terbinafine Therapy in Treatment of Tinea Capitis in Children. Terbinafine, Itraconazole - Tinea Capitis | Not applicable | Completed | Muhammad Aamir Latif | 164 | 2025-04-01 | 2025-11-28 |
| Clinical and Laboratory Evaluation of Antifungal Resistance in Tinea Capitis Terbinafine - Fungal Resistance | Phase 1 | Unknown | Assiut University | 30 | 2024-05-01 | 2024-05-06 |
| Efficacy and Safety of Terbinafine and Itraconazole Terbinafine Tablets, Itraconazole - Tinea Corporis, Tinea Cruris | Phase 2 / Phase 3 | Unknown | Dhaka Medical College | 150 | 2023-05-01 | 2023-05-31 |
| Mycosis Culture Collection From Dermatological Isolated Terbinafine Topical Gel, Itraconazole 200 mg, Terbinafine 250 mg - Onychomycosis, Resistant Infection | Unknown | University of Rome Tor Vergata | 200 | 2022-07-20 | 2024-05-08 | |
| From Fungus to Virus, Investigating the Safety and Efficacy of Terbinafine in Chronic Hepatitis B Patients Terbinafine, Placebo, Tenofovir - Chronic Hepatitis b | Phase 1 / Phase 2 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 36 | 2022-04-13 | 2025-02-07 |
| Comparative Study Between Pulse Therapy With Oral Itraconazole Versus Continuous Oral Terbinafine Therapy for Treatment of Onychomycosis itraconazole, terbinafine - Onychomycosis | Phase 1 | Completed | Combined Military Hospital Abbottabad | 100 | 2022-03-01 | 2022-10-19 |
| Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally., Itraconazole's matching placebo 400 mg/day and terbinafine's matching placebo 500 mg/day administered orally. - Crohn's Disease, Inflammatory Bowel Diseases | Phase 2 | Terminated | Montreal Heart Institute | 16 | 2022-02-22 | 2024-05-30 |
| Efficacy of Intralesional PRP in Treatment of Onychomycosis intralesional platelet rich plasma, Oral terbinafine - Platelet Rich Plasma | Phase 3 | Unknown | Sohag University | 75 | 2021-12-01 | 2021-11-22 |
| Population Pharmacokinetics of Terbinafine in Children With Tinea Capitis Terbinafine Tablets - Tinea Capitis | Recruiting | Shandong University | 60 | 2021-06-15 | 2025-07-02 | |
| Comparison of Efficacy of Double Dose Oral Terbinafine Vs Itraconazole in Treatment of Dermatophyte Infections of Skin. Terbinafine Pill, Itraconazole capsule - Dermatophyte Infection, Terbinafine Adverse Reaction | Phase 3 | Completed | Pak Emirates Military Hospital | 120 | 2021-03-15 | 2022-04-01 |
| Terbinafine Treatment of Axial Spondyloarthropathy Terbinafine Tablets, Laboratory Testing - Ankylosing Spondylitis, Axial Spondyloarthritis | Early Phase 1 | Withdrawn | Oregon Health and Science University | 2021-03-09 | 2023-08-28 | |
| SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS TERBINAFINE HYDROCHLORIDE (1%), BUTENAFINE HYDROCHLORIDE (1%), Vehicle Control - Tinea Pedis | Phase 2 | Unknown | United Laboratories | 42 | 2019-01-02 | 2019-06-26 |
| Laser Treatment for Onychomycosis in Diabetes Laser Treatment YAG laser, Standard Treatment (control group) terbinafine hydrochloride tablets - Diabetes Mellitus, Type 2, Onychomycosis | Not applicable | Unknown | BCDiabetes.Ca | 60 | 2018-07-01 | 2017-02-20 |
| Isotretinoin In Preventing Recurrences In Chronic Recurrent Dermatophytosis Isotretinoin, Terbinafine, Itraconazole 200 mg - Tinea | Phase 2 | Unknown | Post Graduate Institute of Medical Education and Research, Chandigarh | 100 | 2018-04-01 | 2018-05-01 |
Showing 20 of 47. Sign in to see all of them.
Onychomycosis (18) · Tinea Capitis (4) · Tinea Pedis (4) · Foot Dermatoses (3) · Tinea (2) · AIDS-Related Opportunistic Infections (1) · Acute Kidney Injury (1) · Axial Spondyloarthritis (1) · Candidiasis, Oral (1) · Colitis, Ulcerative (1) · Crohn Disease (1) · Dermatitis, Seborrheic (1) · Dermatomycoses (1) · Diabetes Mellitus, Type 2 (1) · Fasting (1)
Novartis (4) · Assiut University (3) · Novartis Pharmaceuticals (3) · Celtic Pharma Development Services (2) · Dr. Reddy's Laboratories Limited (2) · Mylan Pharmaceuticals Inc (2) · Nitric BioTherapeutics, Inc (2) · Roxane Laboratories (2) · Teva Pharmaceuticals USA (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · BCDiabetes.Ca (1) · Cairo University (1) · Can Tho University of Medicine and Pharmacy (1) · Combined Military Hospital Abbottabad (1) · Dhaka Medical College (1)
United States (17) · Canada (7) · China (3) · Pakistan (3) · Finland (2) · France (2) · Germany (2) · Iceland (2) · Egypt (1) · Hungary (1) · Italy (1) · Netherlands (1) · Norway (1) · Philippines (1) · Poland (1)
Eduardo Tschen, MD (2) · Eric Bicrell (2) · James D Carlson, Pharm. D. (2) · Shirley Ann Kennedy, M.D. (2) · Steven Herrmann, MD (2) · Alaa Moubasher, Professor (1) · Atul Deodhar, M.D. (1) · Carl Schanbacher, MD (1) · Dang Khoa Dang Tran, MD (1) · Dr. Umar Abdul Ali Qureshi, MBBS (1) · Edmond-Jean Bernard, MD (1) · Elena Campione (1) · Fahad Iqbal, FCPS (1)
PMID 14964746, PMID 19968146, PMID 21967490, PMID 22565425, PMID 24079585, PMID 24352873, PMID 27297276, PMID 35330222